checkAd

     101  0 Kommentare USANA Health Sciences Reports Third Quarter Results

    USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 2, 2021, which were modestly ahead of the preliminary outlook the Company provided on September 16, 2021.

    Key Financial & Operating Highlights

    • Third quarter net sales were $274.4 million as compared with $298.5 million during the third quarter of the prior year.
    • Third quarter diluted EPS were $1.36 versus $1.44 during the third quarter of 2020.
    • Reiterates fiscal 2021 net sales and diluted EPS outlook, which was provided on September 16, 2021.
    • Company expects to generate approximately $130 million of free cash flow in fiscal 2021.

    Q3 2021 Financial Performance

    Consolidated Results

    Net Sales

    $274.4 million

    • -8% vs. prior-year quarter
    • -11% constant currency vs. prior-year quarter
    • +$9.9 million YOY FX impact, or +3%

    Diluted EPS

    $1.36

    • -6% vs. prior-year quarter
    • Diluted shares of 20.2 million, -5%

    Active Customers

    576,000

    • -11% vs. prior-year quarter

    “As we indicated a month ago, the operating environment remains challenging across several of our key markets due, in great part, to disruptions and lockdowns related to the COVID-19 pandemic,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Additionally, the year-over-year comparison was difficult given the significant short-term sales program that we offered in the prior year quarter. Notwithstanding these challenges, we continue to execute our growth strategy, which is centered on generating sustainable customer growth.”

    Q3 2021 Regional Results:

    Asia Pacific Region

    Net Sales

    $220.9 million

    • -9% vs. prior-year quarter
    • Constant currency net sales: -12%
    • 81% of consolidated net sales

    Active Customers

    443,000

    • -12% vs. prior-year quarter
    • -14% sequentially

    Asia Pacific Sub-Regions

    Greater China

    Net Sales

    $123.2 million

    • -9% vs. prior-year quarter
    • Constant currency net sales: -15%

    Active Customers

    246,000

    • -13% vs. prior-year quarter
    • -19% sequentially

    North Asia

    Net Sales

    $33.1 million

    • +14% vs. prior-year quarter
    • Constant currency net sales: +12%

    Active Customers

    63,000

    • +5% vs. prior-year quarter
    • -5% sequentially

    Southeast Asia Pacific

    Net Sales

    $64.6 million

    • -15% vs. prior-year quarter
    • Constant currency net sales: -15%

    Active Customers

    134,000

    • -15% vs. prior-year quarter
    • -7% sequentially

       

    Americas and Europe Region

    Net Sales

    $53.5 million

    • -7% vs. prior-year quarter
    • Constant currency net sales: -9%
    • 19% of consolidated net sales

    Active Customers

    133,000

    • -10% vs. prior-year quarter
    • -4% sequentially

    Mr. Guest added, “We made progress on several strategic initiatives during the quarter. Enhancing the overall shopping experience for our customers remains a high priority, and to that end, we rolled out additional features and functionality within our China shopping app, as well as a new web-based shopping cart in China. Although our introduction of certain new products has been delayed until 2022, we are actively engaged in bringing new and innovative products to market. Overall, we remain confident that the successful execution of our strategy will deliver long-term, sustainable growth.”

    Balance Sheet and Share Repurchase Activity

    The Company ended the quarter with $249 million in cash and cash equivalents and no debt after repurchasing 523,000 shares for $50 million. Diluted shares outstanding totaled 20.2 million during the third quarter of 2021. As of October 2, 2021, the Company had approximately $137 million remaining under the share repurchase authorization, following the Company’s increase of the repurchase authorization on September 16, 2021.

    Fiscal 2021 Outlook

    The Company is reiterating its net sales and earnings per share outlook for fiscal year 2021, which was provided on September 16, 2021.

    Fiscal Year 2021 Outlook

     

     

    Range

    Consolidated Net Sales

    $1.18 - $1.20 billion

    Diluted EPS

    $5.80 - $6.00

    The Company maintains a 52/53-week fiscal year. Fiscal 2020 was a 53-week year and included one additional week of sales in the fourth quarter of 2020 compared to Fiscal 2021.

    Doug Hekking, Chief Financial Officer, said, “We are reiterating our outlook for fiscal 2021 with third quarter results coming in just ahead of the projections we provided on September 16th. Our outlook incorporates ongoing investments required to achieve long-term growth objectives that may impact near-term operating margins.”

    Management Commentary Document and Conference Call

    For more information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, October 27, 2021 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

    Non-GAAP Financial Measures

    The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results. Free cash flow is a non-GAAP financial measure that we believe provides investors an additional perspective on cash flow from operating activities in excess of amounts required for reinvestment. We believe it provides a measure of our ability to fund various discretionary business initiatives, including acquisitions and share repurchase. Free cash flow is calculated by subtracting net capital expenditures from net cash provided by operating activities.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found at www.usana.com.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic (“COVID-19”) to our business, operations and financial results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

    USANA Health Sciences, Inc.
    Consolidated Statements of Operations
    (In thousands, except per share data)
    (Unaudited)
     

    Quarter Ended

     

    Nine Months Ended

    2-Oct-21

     

    26-Sep-20

     

    2-Oct-21

     

    26-Sep-20

     
    Net sales

    $

    274,352

     

    $

    298,513

     

    $

    919,165

    $

    824,123

     

    Cost of sales

     

    50,715

     

     

    56,358

     

     

    165,380

     

    150,091

     

    Gross profit

     

    223,637

     

     

    242,155

     

     

    753,785

     

    674,032

     

    Operating expenses:
    Associate incentives

     

    116,222

     

     

    131,144

     

     

    404,580

     

    358,065

     

    Selling, general and administrative

     

    66,645

     

     

    65,656

     

     

    210,518

     

    192,014

     

    Earnings from operations

     

    40,770

     

     

    45,355

     

     

    138,687

     

    123,953

     

    Other income (expense), net

     

    (420

    )

     

    (1,080

    )

     

    309

     

    (536

    )

    Earnings before income taxes

     

    40,350

     

     

    44,275

     

     

    138,996

     

    123,417

     

    Income taxes

     

    13,020

     

     

    13,769

     

     

    42,811

     

    38,382

     

    NET EARNINGS

    $

    27,330

     

    $

    30,506

     

    $

    96,185

    $

    85,035

     

     
     
    Earnings per share - diluted

    $

    1.36

     

    $

    1.44

     

    $

    4.68

    $

    4.00

     

    Weighted average shares outstanding - diluted

     

    20,156

     

     

    21,170

     

     

    20,566

     

    21,283

     

    USANA Health Sciences, Inc.
    Consolidated Balance Sheets
    (In thousands)
    (Unaudited)
     

    As of

    As of

    2-Oct-21

    2-Jan-21

    ASSETS
    Current Assets
    Cash and cash equivalents

    $

    248,695

    $

    311,917

    Inventories

     

    96,316

     

    90,224

    Prepaid expenses and other current assets

     

    23,414

     

    23,145

    Total current assets

     

    368,425

     

    425,286

     
    Property and equipment, net

     

    100,957

     

    100,445

    Goodwill

     

    17,510

     

    17,367

    Intangible assets, net

     

    30,312

     

    30,796

    Deferred tax assets

     

    5,465

     

    4,640

    Other assets

     

    56,277

     

    62,353

    Total assets

    $

    578,946

    $

    640,887

     
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current Liabilities
    Accounts payable

    $

    13,706

    $

    18,195

    Other current liabilities

     

    144,258

     

    149,878

    Total current liabilities

     

    157,964

     

    168,073

     
    Deferred tax liabilities

     

    7,840

     

    12,009

    Other long-term liabilities

     

    14,063

     

    19,155

     
    Stockholders' equity

     

    399,079

     

    441,650

    Total liabilities and stockholders' equity

    $

    578,946

    $

    640,887

    USANA Health Sciences, Inc.
    Sales by Region
    (unaudited)
    (in thousands)
     
    Quarter Ended
    October 2, 2021 September 26, 2020 Change from prior year Currency
    impact on
    sales
    % change
    excluding
    currency impact
    Asia Pacific
    Greater China

    $

    123,235

    44.9

    %

    $

    136,013

    45.5

    %

    $

    (12,778

    )

    (9.4

    %)

    $

    7,457

    (14.9

    %)

    Southeast Asia Pacific

     

    64,570

    23.5

    %

     

    76,313

    25.6

    %

     

    (11,743

    )

    (15.4

    %)

     

    85

    (15.5

    %)

    North Asia

     

    33,068

    12.1

    %

     

    28,969

    9.7

    %

     

    4,099

     

    14.1

    %

     

    770

    11.5

    %

    Asia Pacific Total

     

    220,873

    80.5

    %

     

    241,295

    80.8

    %

     

    (20,422

    )

    (8.5

    %)

     

    8,312

    (11.9

    %)

     
    Americas and Europe

     

    53,479

    19.5

    %

     

    57,218

    19.2

    %

     

    (3,739

    )

    (6.5

    %)

     

    1,570

    (9.3

    %)

    $

    274,352

    100.0

    %

    $

    298,513

    100.0

    %

    $

    (24,161

    )

    (8.1

    %)

    $

    9,882

    (11.4

    %)

    Active Associates by Region(1)
    (unaudited)
     
    As of
    October 2, 2021 September 26, 2020
    Asia Pacific
    Greater China

    81,000

    29.8%

    91,000

    29.1%

    Southeast Asia Pacific

    90,000

    33.1%

    113,000

    36.1%

    North Asia

    39,000

    14.3%

    39,000

    12.4%

    Asia Pacific Total

    210,000

    77.2%

    243,000

    77.6%

     
    Americas and Europe

    62,000

    22.8%

    70,000

    22.4%

    272,000

    100.0%

    313,000

    100.0%

     
     
    Active Preferred Customers by Region (2)
    (unaudited)
     

    As of

    October 2, 2021

    September 26, 2020

    Asia Pacific
    Greater China

    165,000

    54.3%

    193,000

    57.3%

    Southeast Asia Pacific

    44,000

    14.4%

    45,000

    13.4%

    North Asia

    24,000

    7.9%

    21,000

    6.2%

    Asia Pacific Total

    233,000

    76.6%

    259,000

    76.9%

     
    Americas and Europe

    71,000

    23.4%

    78,000

    23.1%

    304,000

    100.0%

    337,000

    100.0%

    (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.
    (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

     




    Business Wire (engl.)
    0 Follower
    Autor folgen

    USANA Health Sciences Reports Third Quarter Results USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 2, 2021, which were modestly ahead of the preliminary outlook the Company provided on September 16, 2021. Key Financial & Operating …